OneMedNet Corporation announced that its real‑world data (iRWD) network has grown to more than 186 million clinical exams and 2,130 provider sites, an increase of 37 % in exams and 38 % in patient records over the three months ending November 20, 2025. The expansion brings the company’s data repository to a scale that rivals the largest global RWE platforms, positioning OneMedNet as a key player in the $60 billion real‑world evidence market.
The deeper data set directly strengthens OneMedNet’s subscription model. Pharmaceutical, life‑science, and AI customers now have access to larger, more diverse, and longitudinal cohorts, which increases the value of each subscription contract. Aaron Green, president and CEO, noted that the expanded network “materially enhances the depth, specificity, and value of those data feeds,” creating a virtuous cycle where existing subscribers expand commitments and new customers sign long‑term agreements.
Despite the operational milestone, OneMedNet’s financial health remains fragile. Q3 2025 revenue rose to $0.177 million from $0.142 million a year earlier, yet the company still reports negative gross margins and a substantial operating loss. The company disclosed a “substantial doubt about the ability to continue as a going concern” due to low cash reserves and high current liabilities as of September 30, 2025. The expansion is therefore a strategic win that must be weighed against ongoing liquidity and profitability challenges.
Green highlighted the company’s focus on debt reduction and capital infusions, which have enabled a more resilient sales pipeline and a 4.5‑fold increase in inbound demand. He also emphasized the partnership with Palantir Technologies, which is accelerating the delivery of AI‑powered subscription models and improving data discovery and de‑identification across the network.
Market reaction to the announcement has been muted. While the company’s stock has trended downward in the days surrounding the release, analyst sentiment remains largely negative, with a consensus “sell” rating. Investors appear to be prioritizing the company’s liquidity concerns and negative margins over the operational expansion.
In summary, OneMedNet’s iRWD network expansion represents a significant operational achievement that enhances its subscription value proposition. However, the company’s ongoing financial headwinds and going‑concern warning underscore the need for continued capital discipline and strategic focus on high‑margin AI services to sustain long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.